SCYNEXIS (SCYX) AI Stock Analysis

• Market Cap: $39.93M
• Dividend Yield: N/A
• Average Volume (3M): 612.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -65.77%
• EPS Growth: 38.61%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.25
• Shares Outstanding: 44,663,834
• 10 Day Avg. Volume: 689,890
• 30 Day Avg. Volume: 612,753
• PEG Ratio: 0.06
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 1.53
• P/FCF Ratio: -5.98
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 1.01
• Enterprise Value/Gross Profit: 1.01
• Enterprise Value/Ebitda: 1.27
• 1Y Price Target: $3.50
• Price Target Upside: 430.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.45
• Revenue Forecast (FY): $1.15M

• Rating: 50 Neutral
• Price Target: $0.89 ▲(35.15% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held back primarily by inconsistent and currently loss-making financial performance (negative margins and negative free cash flow). The strengthened, low-leverage balance sheet is the main offsetting positive, while technical indicators are neutral-to-slightly positive and valuation is constrained by negative earnings and no dividend support.

Positive Factors

Low Leverage / Strong Balance Sheet

Material reduction in debt and a low debt-to-equity ratio give SCYNEXIS durable financial flexibility to fund R&D, pursue partnerships or weather operating losses without immediate refinancing. The sizable equity base (~$49.4M vs $59.0M assets) supports strategic optionality.

Approved Commercial Product

Having an approved, orally administered antifungal provides a persistent commercial foundation: product sales and licensing can generate recurring revenue, enable market expansion across indications/formulations, and create barriers for new entrants due to regulatory approval.

Demonstrated Commercial Recovery

The sharp 2025 revenue rebound and prior 2023 commercialization peak demonstrate the company's ability to generate meaningful sales when commercial execution aligns. This track record supports a view that Brexafemme can drive sustainable top-line if launch and partner dynamics remain constructive.

Negative Factors

Revenue Volatility

Large swings in revenue undermine predictability for budgeting, R&D investment, and commercialization scale-up. Such volatility complicates forecasting, weakens negotiating leverage with partners/payors, and raises execution risk that revenue may revert absent stable demand drivers.

Persistent Negative Margins

Substantial negative margins indicate the business has not yet achieved sustainable profitability. Continued losses necessitate external financing or dilutive deals, constrain reinvestment capacity, and heighten the risk that equity value could be eroded if operating performance doesn't improve.

Negative and Cyclical Cash Flow

Ongoing negative free cash flow, despite improvement, means the company must rely on financing or partnerships to fund operations and growth. The cyclical cash history increases execution risk and limits the firm's ability to consistently invest in commercialization or pipeline programs without external capital.

SCYNEXIS Business Overview & Revenue Model

Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

How the Company Makes Money

SCYNEXIS generates revenue primarily from (1) product sales of its approved antifungal, Brexafemme (ibrexafungerp), through commercialization in markets where it or its commercial partners sell the product, and (2) collaboration-related income such as upfront payments, milestones, and potentially royalties under licensing or partnering arrangements for development and/or commercialization of its assets in specified territories or indications. Its earnings are therefore influenced by prescription demand and pricing/reimbursement dynamics for Brexafemme, the scope and performance of any commercial partners in licensed regions, and the achievement of clinical, regulatory, and commercial milestones tied to partnered programs. If SCYNEXIS has recognized other income (e.g., grant revenue or interest income) in its financial statements, those would generally be secondary to product and collaboration revenue. Specific current partners, deal terms, and the relative size of each revenue stream are null.

SCYNEXIS Financial Statement Overview

Summary

Balance sheet strength is the key positive (very low debt and solid equity base), but operating performance remains weak with volatile revenue, negative margins, and still-negative free cash flow despite reduced cash burn.

Income Statement

Revenue rebounded sharply in 2025 ($20.6M; +603% YoY) after a steep drop in 2024 ($3.7M) from an unusually strong 2023 ($140.1M), indicating a highly volatile top line. Profitability is currently weak: 2025 net margin was about -42% with negative EBITDA, following large losses in 2024, while 2023 was strongly profitable. Overall, the trajectory shows inconsistent earnings power and limited margin stability despite the recent revenue recovery.

Balance Sheet

Leverage has improved materially versus earlier years: total debt fell to $2.2M in 2025 from $16.3M in 2024 and $48.6M in 2022, and debt-to-equity is low at ~0.04 in 2025. Equity is sizable ($49.4M) relative to assets ($59.0M), supporting balance-sheet flexibility. The key weakness is ongoing losses, reflected in negative returns on equity in 2024–2025, which could pressure the equity base over time if not reversed.

Cash Flow

Cash generation remains a concern: operating cash flow and free cash flow were negative again in 2025 (-$5.3M), though improved significantly from 2024 (-$24.0M). Cash flow has been highly cyclical, with a strong positive year in 2023 (+$60.2M) sandwiched between heavy outflows in 2020–2022 and 2024–2025. The main strength is the meaningful reduction in cash burn versus 2024; the main risk is that free cash flow is still negative and has not stabilized.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	20.60M	3.75M	140.14M	5.09M	13.16M
Gross Profit	20.60M	3.75M	124.52M	4.46M	12.85M
EBITDA	-16.07M	-18.58M	70.89M	-59.91M	-32.91M
Net Income	-8.61M	-21.29M	67.04M	-62.81M	-32.87M
Balance Sheet
Total Assets	59.03M	90.64M	128.41M	87.81M	119.84M
Cash, Cash Equivalents and Short-Term Investments	21.26M	59.30M	74.36M	73.50M	104.48M
Total Debt	2.17M	16.27M	15.08M	48.60M	43.63M
Total Liabilities	9.65M	35.57M	55.45M	84.58M	78.58M
Stockholders Equity	49.38M	55.08M	72.96M	3.23M	41.26M
Cash Flow
Free Cash Flow	-5.28M	-24.01M	60.16M	-79.89M	-55.73M
Operating Cash Flow	-5.28M	-24.01M	60.16M	-79.88M	-54.56M
Investing Cash Flow	24.31M	6.15M	-34.88M	-27.39M	-1.17M
Financing Cash Flow	-14.17M	-139.00K	-36.72M	48.60M	67.12M

SCYNEXIS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Positive. The current price of 0.66 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.76, and below the 200-day MA of 0.77, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 73.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCYX.

SCYNEXIS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	52 Neutral	$25.81M	20.56	0.27%	―	75.19%	―
CPIX	52 Neutral	$43.08M	-20.99	-10.54%	―	12.21%	69.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCYX	50 Neutral	$39.93M	-3.67	-19.05%	―	-65.77%	38.61%
AYTU	45 Neutral	$27.80M	-0.62	-107.16%	―	-15.61%	-68.96%
RMTI	42 Neutral	$40.59M	-6.17	-16.77%	―	-23.60%	-179.33%
IMCC	40 Underperform	$3.43M	-0.89	-93.87%	―	-0.74%	81.49%